1.
Agirre X, Fontalba A, Andreu E, Odero M, Larrayoz M, Montiel C, Calasanz M, Fernandez-Luna J, Prosper F. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response. Haematologica 2003; 88(12):1425-1426.